Journal article
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
- Abstract:
-
Objective: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes with clinical outcomes of baricitinib treatment.
Methods: An integrated analysis was conducted by pooling data from three completed Phase 3 trials comparing placebo and baricitinib treatment...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Incyte Corporation
More from this funder
Eli Lilly and Company
More from this funder
Bibliographic Details
- Publisher:
- John Wiley and Sons, Ltd. Publisher's website
- Journal:
- Arthritis and Rheumatology Journal website
- Volume:
- 70
- Issue:
- 12
- Pages:
- 1923-1932
- Publication date:
- 2018-07-29
- Acceptance date:
- 2018-06-27
- DOI:
- EISSN:
-
2326-5205
- ISSN:
-
2326-5191
- Source identifiers:
-
860150
Item Description
- Pubs id:
-
pubs:860150
- UUID:
-
uuid:ce0aca2b-d59a-4549-8a52-7f0315b79753
- Local pid:
- pubs:860150
- Deposit date:
- 2018-07-02
Terms of use
- Copyright holder:
- Eli Lilly and Company
- Copyright date:
- 2018
- Notes:
- © 2018 Eli Lilly and Company. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made
If you are the owner of this record, you can report an update to it here: Report update to this record